Written by Marcus Chen
One of the more revealing healthcare developments of the last forty-eight hours did not come from a trial readout or an FDA label expansion. It came from RDi USA launching at ADLM 2026 with a pitch built around automated diagnostic kitting and connected self-sampling pathways for the U.S. market. That may sound operational rather than scientific. In reality, it captures a deeper shift in diagnostics: the sector is increasingly competing not only on test performance, but on how smoothly samples can be captured, moved, and integrated into usable care pathways.
For much of the modern diagnostics era, value was concentrated in the assay, the instrument, or the central lab. Those assets still matter. But as healthcare systems become more distributed, the logistical layer around testing becomes more strategic. Self-sampling, remote capture, and connected kit management all aim to solve a stubborn problem: valuable diagnostic information often depends on infrastructure that is too centralized, too inconvenient, or too slow for the settings where patients actually engage the system.
RDi’s framing is therefore important because it treats sample capture as a design problem rather than an afterthought. Automated kitting and connected self-sampling pathways suggest a business model in which the test is only part of the product. The rest of the product is the operational pathway that lets the right sample be collected, matched, tracked, and routed with minimal friction.
| Traditional diagnostics model | Emerging distributed diagnostics model |
| Clinical value is concentrated in the lab and assay | Clinical value increasingly includes how samples are gathered and moved |
| Sampling is an inconvenient precursor to testing | Sampling becomes part of the competitive product architecture |
| Diagnostics are infrastructure-heavy and site-dependent | Diagnostics become more modular and geographically flexible |
| Quality is associated mainly with centralized control | Quality must coexist with distributed convenience and pathway design |
This matters because distributed diagnostics is not just a convenience story. It is a healthcare infrastructure story. If sample collection becomes easier, more connected, and more standardized outside traditional clinical settings, then testing can happen at larger scale and with less dependence on centralized touchpoints. That affects screening economics, chronic monitoring, public-health responsiveness, and patient adherence.
It also changes where companies can build defensible positions. A superior assay can be copied or competed against over time. A deeply integrated logistics-and-sampling pathway can become sticky in a different way, especially if it reduces failure points across ordering, collection, transport, and data linkage. In that sense, the next diagnostics winners may look less like instrument vendors and more like workflow infrastructure companies.
There are, of course, real challenges. Distributed sample capture creates risks around chain of custody, specimen quality, user error, reimbursement, and regulatory consistency. The more testing moves away from tightly controlled collection settings, the more important system design becomes. Convenience without reliability can destroy trust very quickly.
Still, that is precisely why RDi’s positioning is worth watching. The company is effectively betting that the bottleneck in diagnostics is shifting from pure analytic capability toward pathway execution. If that thesis is right, then future value in the sector may be created not only by discovering better biomarkers, but by building better ways to bring testing into ordinary patient flow.
Healthcare’s next diagnostics battle may therefore be fought less over who owns the best machine and more over who owns the most usable sampling infrastructure. RDi’s U.S. launch suggests that distributed diagnostics is beginning to mature from a peripheral convenience concept into a serious operating model.
